tiprankstipranks
Alkermes price target raised to $28 from $27 at BofA
The Fly

Alkermes price target raised to $28 from $27 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Alkermes (ALKS) to $28 from $27 and keeps a Neutral rating on the shares after the company was granted an interim award in its arbitration proceeding with Johnson & Johnson (JNJ). While not a final award, the update "reads, at a minimum, directionally positive" to Alkermes as the company may recoup part or all foregone royalty revenue on U.S. Invega from February 2022 to the 2024 end of know-how period, Gerberry tells investors in a research note. The analyst, however, still sees a balanced risk/reward on shares of Alkermes.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on ALKS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles